Search the Newsreel

Bicycle Therapeutics PLC (BCYC) Earnings Forecast: Future EPS & Revenue Growth Estimates

BCYC|Bicycle Therapeutics PLC|Price:3.875|Chg%:+0.015

Bicycle Therapeutics PLC (BCYC) shows strong fundamentals and significant growth potential, despite recent weak market performance. TradingKey's analysis rates its valuation as fairly valued, with high institutional ownership. Analysts have given the stock a "Buy" rating, setting a high price target, though the stock …

Bicycle Therapeutics plc Stock 12‑Month Price Target Cut to $10.29, Implies 166% Upside

Bicycle Therapeutics plc (BCYC) has seen its average 12-month price target cut to $10.29 from $10.43 by 7 analysts, implying a potential upside of 166% from its July 29 closing price. Despite the target reduction, the consensus rating from 9 covering analysts remains "Buy," …

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Bicycle Therapeutics Stock Price Forecast. Should You Buy BCYC?

Bicycle Therapeutics (BCYC) Expected to Post Earnings on Friday

Bicycle Therapeutics Releases Q2 2026 Financial Results

Bicycle Therapeutics plc reported a narrower loss in Q2 2026 despite a significant drop in revenue. The clinical-stage pharmaceutical company posted a loss per share of $0.72, an improvement from the previous year, while revenue decreased by 78.5% to $629,000. Wall Street analysts maintain …

BCYC Looks 71.0% Undervalued on GF Value™ Despite Revenue Drop

Bicycle Therapeutics PLC (BCYC) reported a significant Q2 revenue decline, yet its GF Value™ suggests the stock is 71.0% undervalued. The company, a clinical-stage biotech, is focused on advancing its cancer pipeline despite being unprofitable and cash-flow negative, with a moderate GF Score™ indicating …

Bicycle Therapeutics PLC 2026: Revenue $629K, EPS ($0.72) — 10-Q Summary

Bicycle Therapeutics PLC reported collaboration revenue of $629K and a net loss of ($50.33M) for the quarter ended 2026, with a diluted loss per share of ($0.72). This represents a significant decrease in revenue but an improvement in net loss compared to the prior …

Bicycle Therapeutics reports Q2 2026 results — $510.1M cash, $50.3M net loss

Bicycle Therapeutics has released its Q2 2026 results, showing $510.1 million in cash and cash equivalents and a net loss of $50.3 million. The company reported reduced R&D and G&A expenses year-over-year and projects a cash runway into 2030, citing clinical advancements in its …

Bicycle’s zelenectide shows 65% overall response rate in 26 patients

Bicycle Therapeutics reported its Q2 2026 financial results, including a net loss of $50.3 million, and provided corporate updates. Key clinical data were presented for nuzefatide pevedotin in EphA2-expressing cancers and for zelenectide pevedotin in metastatic urothelial cancer, showing promising anti-tumor activity and differentiated …

Bicycle Therapeutics (NASDAQ: BCYC) cuts costs, ends Bayer deal as cash tops $510M

Bicycle Therapeutics earnings missed by $0.15, revenue fell short of estimates

Bicycle Therapeutics (NASDAQ: BCYC) reported second-quarter earnings per share of $-0.72, missing analyst estimates by $0.15. The company's revenue for the quarter was $630K, falling short of the consensus estimate of $4.35M. Following the announcement, Bicycle Therapeutics' stock price closed at $3.86, reflecting a …

Bicycle Therapeutics PLC (BCYC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Bicycle Therapeutics PLC (BCYC), noting its current valuation score of 7.52, which ranks it 215 out of 384 in the Biotechnology & Medical Research industry. It details the company's current P/E ratio of -1.22 and indicates that …

Bicycle Therapeutics Plc Sponsored ADR Revenue Breakdown – DUS:50BA

Bicycle Therapeutics Plc Sponsored ADR (DUS:50BA) generated €61.80 million in revenue last year, primarily from its Chemically Synthesized Medicines segment. The United Kingdom was the largest contributor to this revenue. This marks an increase from the previous year's revenue of €34.07 million.

Bicycle Therapeutics plc Stock 12‑Month Price Target Cut to $10.43, Implies 165% Upside

Bicycle Therapeutics plc (BCYC) has seen its average 12-month price target cut to $10.43 from $13.62 by analysts, with a range of forecasts from $5 to $15 per share. Despite the cut, this new target implies a potential upside of approximately 165% from the …

Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Bicycle Therapeutics PLC (BCYC), detailing its business segments, regional revenue, and profit contribution. However, it states that the relevant financial data for these categories has not yet been disclosed by the company. The page also includes current …

Bicycle Therapeutics PLC (BCYC) Cash Flow

This article provides the quarterly and annual cash flow statements for Bicycle Therapeutics PLC (BCYC), detailing operating, investing, and financing cash flows. It includes historical data reaching back to 2017Q4 and highlights key financial metrics such as net income from continuing operations, capital expenditures, …

Bicycle Therapeutics PLC (BCYC) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Bicycle Therapeutics PLC (BCYC)'s dividend and stock split history, indicating that the company has not distributed any dividends over the past five years. It also includes current stock performance data, showing BCYC trading at $3.960 with a 2.33% …

TradingKey

This article provides a detailed quarterly and annual income statement for Bicycle Therapeutics PLC (BCYC), spanning from FY2017Q4 to FY2026Q1. It breaks down various financial metrics including total revenue, operating expenses, R&D expenses, operating profit, non-operating income/expenses, income before tax, income tax, net income, …

BCYC|Bicycle Therapeutics PLC|Price:3.870|Chg%:-0.070

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing a new class of medicines called Bicycle molecules for underserved diseases. The company is evaluating several drug candidates, including zelenectide pevedotin, BT5528, and BT7480, in clinical trials for oncology. They are also exploring …

Bicycle Therapeutics PLC (BCYC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Bicycle Therapeutics PLC (BCYC), outlining major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The data includes the …

Bicycle Therapeutics PLC (BCYC) Institutional Confidence

Bicycle Therapeutics PLC (BCYC) has an institutional shareholding score of 5.00, placing it 132nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 67.23%, a decrease of 41.32% quarter-over-quarter. James Simons is the largest institutional shareholder despite a decrease in holdings.

Bicycle Therapeutics PLC (BCYC) Financial Health: Profitability & Balance Sheet Analysis

Bicycle Therapeutics PLC (BCYC) has a current financial score of 6.38, ranking 257 out of 386 in its industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 91.11% year-over-year to $887.00K, while net profit saw a 0.12% …

Frontier tech research, news & data

This article provides an update on an insider transaction for BICYCLE THERAPEUTICS PLC (BCYC). A Form 3/4/5 filing was made on July 17, 2026, which can be viewed on SEC.gov. The article also mentions a "Power Delivery Gap Report" available from MLQ.ai, analyzing the …

Bicycle Therapeutics (BCYC) grants 60,000 stock options to CSO

Bicycle Therapeutics plc's Chief Scientific Officer, Michael Skynner, was granted 60,000 employee stock options on July 15, 2026. These options allow for the purchase of Ordinary Shares at an exercise price of $4.21 per share and will vest over time, with one-fourth vesting on …

Bicycle Therapeutics (BCYC) awards 60,000 options to supply chain chief

Bicycle Therapeutics (BCYC) has granted its Chief Product and Supply Chain Officer, Michael Charles Ferguson Hannay, 60,000 employee stock options. The options have an exercise price of $4.21 per share and expire on July 15, 2036. The vesting schedule begins with one-fourth of the …

BICYCLE THERAPEUTICS PLC 4 — Jul 17, 2026 · MLQ

The article reports an insider transaction for Bicycle Therapeutics PLC, filed on July 17, 2026. It notes that the transaction details are available on SEC.gov, with the source document served from SEC EDGAR. The page also promotes a research report titled "The Power Delivery …

Bicycle Therapeutics (BCYC) Holds Gains as Shares Test Resistance Near $4.50 - Butterfly Setup

Five ASCO studies put Bicycle Therapeutics' cancer drug in focus

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bicycle Therapeutics (BCYC) Quarterly Loss Of US$59.1 Million Tests Growth Focus Narrative